rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
2024 · Molecular Cancer · 25 citations
https://doi.org/10.1186/s12943-024-01976-2
L
Luigi Liguori
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
36
Papers
553
Citations
11
h-index
11
i10-index
Luigi Liguori is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Lung Cancer Treatments and Mutations & Lung Cancer Research Studies. The author has an h-index of 11, co-authored 31 publications.
ORCID: 0000-0002-0232-1452Papers by this author
worksEpigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanoma
2025 · Translational Oncology · 1 citations
https://doi.org/10.1016/j.tranon.2025.102452
Association between opioid use and survival in advanced non small cell lung cancer patients treated with immune checkpoint inhibitors
2025 · Scientific Reports · 1 citations
https://doi.org/10.1038/s41598-025-15684-4
Recurrence in Patients With Lymph Node-Negative Pancreatic Neuroendocrine Tumors
2025 · JAMA Surgery · 1 citations
https://doi.org/10.1001/jamasurg.2025.5401
Coupling PD-L1 Inhibition and Lysosomal Degradation: Innovative Anti-PD-L1 Peptides for NSCLC Immunotherapy
2026 · Journal of Medicinal Chemistry · 1 citations
https://doi.org/10.1021/acs.jmedchem.5c02586
BRCA1-Associated Protein 1 (BAP1) in Human Cancer and its Emerging Role as a Novel Potential Therapeutic Target
2026 · Current Oncology Reports · 0 citations
https://doi.org/10.1007/s11912-026-01749-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat